Cellectis Files 6-K, Incorporates Exhibit 99.1
Ticker: CLLS · Form: 6-K · Filed: May 12, 2025 · CIK: 1627281
Sentiment: neutral
Topics: filing, registration-statement, sec
TL;DR
Cellectis 6-K filed: Exhibit 99.1 incorporated into F-3/S-8 filings.
AI Summary
Cellectis S.A. filed a Form 6-K on May 12, 2025, reporting information for its registration statements. The filing incorporates by reference information from Exhibit 99.1 into its existing Form F-3 and Form S-8 registration statements.
Why It Matters
This filing updates registration statements, potentially impacting how investors view the company's ongoing securities offerings and disclosures.
Risk Assessment
Risk Level: low — This is a routine administrative filing that incorporates previously disclosed information.
Key Players & Entities
- Cellectis S.A. (company) — Registrant
- May 12, 2025 (date) — Filing Date
- Form 6-K (document) — Filing Type
- Exhibit 99.1 (document) — Incorporated Exhibit
- Form F-3 (document) — Registration Statement Type
- Form S-8 (document) — Registration Statement Type
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report information and incorporate by reference Exhibit 99.1 into Cellectis S.A.'s existing registration statements on Form F-3 and Form S-8.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed on May 12, 2025.
Which registration statements are being updated by this filing?
The filing updates registration statements on Form F-3 (Nos. 333-265826 and 333-284302) and Form S-8 (multiple numbers listed).
What type of company is Cellectis S.A.?
Cellectis S.A. is a company in the Biological Products sector, specifically focusing on biological products (no diagnostic substances).
Where is Cellectis S.A. headquartered?
Cellectis S.A. is headquartered at 8, rue de la Croix Jarry, 75013 Paris, France.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 12, 2025 regarding Cellectis S.A. (CLLS).